Researchers have identified the Nrf2-HMOX1 pathway as a key regulator of cisplatin resistance in non-small cell lung cancer (NSCLC), revealing its role in suppressing ferroptosis and helping tumor cells evade chemotherapy-induced death. The study used advanced molecular biology and in vitro/in vivo models to map how Nrf2 regulates antioxidant genes, particularly HMOX1, which modulates oxidative stress to favor tumor survival. This discovery offers a promising target for overcoming drug resistance in one of the deadliest cancers.